CONTRACEPTIVE VACCINE DEVELOPMENT

被引:24
作者
ALEXANDER, NJ
BIALY, G
机构
[1] Contraceptive Development Branch and Center for Population Research, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, 20892
关键词
D O I
10.1071/RD9940273
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Recent advances in antigen definition and production have made the development of a contraceptive vaccine more attainable. Such a vaccine must evoke an immune response that blocks an indispensable step in the reproductive process. Vaccine research involves many approaches to fertility prevention. Vaccines are being developed that could interrupt fertility by inhibition of gonadotrophin release, the function of follicle-stimulating hormone or the effects of human chorionic gonadotrophin (hCG); alternatively, they may prevent fertilization by interfering with the transport of spermatozoa or with sperm-zona pellucida binding. The most advanced prototype is a vaccine based on antibodies to beta hCG. Such vaccines are being studied for clinical efficacy. Many hurdles remain in contraceptive vaccine development. Since the antigens are peptides or small proteins, the resultant immune response is usually moderate, and better adjuvants and delivery systems must be developed to enhance and maintain the immune response. Improvement of the mucosal immune response may be necessary for vaccines incorporating sperm antigens. Research on vaccines that control fertility has resulted in a fascinating base of scientific knowledge that, it is hoped, can be converted into products that will allow another option for individuals who wish to control their fertility.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 62 条
[1]   USE OF NEW VECTORS FOR THE DEVELOPMENT OF VACCINES [J].
ADAMS, SE ;
PAOLETTI, E .
AIDS, 1993, 7 :S141-S146
[2]  
AGGRAWAL A, 1992, AIDS RES HUM RETROV, V8, P942
[3]  
AITKEN RJ, 1990, CONRAD W S, P293
[4]  
ALEXANDER NJ, 1972, J REPROD FERTIL, V31, P399
[5]  
ALEXANDER NJ, 1987, FERTIL STERIL, V47, P192
[6]  
ALEXANDER NJ, 1992, 7TH INT C MUC IMM PR, P8
[7]  
ALEXANDER NJ, 1992, VACCINE RES, V1, P331
[8]   LIPOSOMES AS IMMUNOLOGICAL ADJUVANTS [J].
ALLISON, AC ;
GREGORIADIS, G .
NATURE, 1974, 252 (5480) :252-252
[9]  
APRILE MA, 1966, C J PUBLIC HEALTH, V57, P343
[10]   THE NON-SPECIFIC ENHANCEMENT OF ALLERGY .2. PRECIPITATION OF ANAPHYLACTIC INVITRO RESPONSE CAPACITY AND SERUM IGE AND IGG2A ANTIBODY-SYNTHESIS IN PRIMED BUT NON-RESPONDING RATS BY INJECTION OF ALUM [J].
BERGSTRAND, H ;
ANDERSSON, I ;
NYSTROM, I ;
PAUWELS, R ;
BAZIN, H .
ALLERGY, 1983, 38 (04) :247-260